Skip to content

Compare medicines

Put up to three medicines side by side. Useful for alternatives in the same class, or for seeing how two very different treatments differ.

Attribute
In shortIV antiviral for COVID-19.COVID-19 antiviral pills for people at high risk.
Body systemAntiviralsAntivirals
Drug classRNA polymerase inhibitorsViral protease inhibitors
SupplyPrescription onlyPrescription only
Main usesCOVID-19 in hospital, Early COVID-19 in high-risk outpatients (3 days)Mild to moderate COVID-19 in people at high risk of severe disease
How it worksSlips into the virus's genetic material as it's copied and stops the process.Blocks the enzyme the coronavirus uses to cut its proteins into working parts.
Starts working——
Half-lifeAbout 1 hour (parent); metabolites longerAbout 6 hours
Typical adult dose200 mg on day 1, then 100 mg daily.300 mg nirmatrelvir + 100 mg ritonavir twice a day for 5 days, started within 5 days of symptoms (lower dose in moderate kidney disease).
FormsIV infusionCo-packaged tablets
Common side effectsNausea, Raised liver enzymesAltered taste ('Paxlovid mouth'), Diarrhoea, Nausea
Serious side effectsInfusion reactions, Slow heart rate, Liver injuryDangerous interactions with other medicines, Allergic reactions
Don't take if——
Alcohol——
PregnancyUse with cautionUsed when benefits outweigh risks.Use with cautionCan be used if benefits outweigh risks; limited data.
Breastfeeding——
In use since20202021
Brand namesUnited States: VekluryUnited Kingdom: VekluryIndia: Covifor, CipremiUnited States: PaxlovidUnited Kingdom: PaxlovidAustralia: Paxlovid
Legal status——
ATC codeJ05AB16—

Taken together

No interaction between these medicines is recorded in the atlas.

Open in the interaction checker